Announcement

Download

  • Monthly
    Established in 1973
    Responsible Institution
    Health Commission of Hubei Province
    Sponsors
    Hubei Cancer Hospital
    Chinese Anti-Cancer Association
    Editing
    Editorial Board of Cancer Research on Prevention and Treatment
    Editor-in-Chief
    Wei Shaozhong
    CSSN
    ISSN 1000-8578
    CN 42-1241/R
    Subscription Code 38-70
    Code: MO6482
    Tel:027-87670126
    E-mail: zlfzyjzz@vip.163.com
    Add:116 Zhuodaoquan South Road, Hongshan District,Wuhan 430079,China
    Price: RMB 20.00
Core Periodical of Chinese Science and Technology
Chinese Science Citation Database Source Journal (CSCD)
Chinese Core Academic Journal of RCCSE (A)
Scopus, Netherland
DOAJ, Sweden
EBSCO, America
ProQuest, America
CA, America
Ulrichsweb, America
CABI, Britain
JSTChina, Japan
IC, Poland
HINARI, Switzerland
Current Issue
  25 November 2022, Volume 49 Issue 11 Previous Issue   
For Selected: View Abstracts Toggle Thumbnails
Research Status and Progress on Treatment of Advanced Gastric Cancer
DONG Caixia, YUAN Ying
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1095-1102.   DOI: 10.3971/j.issn.1000-8578.2022.22.0596
Abstract ( 64 PDF (0KB)  ( 30 )   HTML ()
Gastric cancer is one of the most common malignant tumors worldwide. The number of gastric cancer cases and related deaths in China accounts for almost half of the global data. The survival prognosis of advanced gastric cancer is poor. With the development of individualized precision therapy, targeted therapy and immunotherapy have become the focus of comprehensive therapy. This paper reviews the latest research progress of chemotherapy, targeted therapy, and immunotherapy for advanced gastric cancer.
Research Progress of Diagnosis and Treatment of Glioblastoma
CHEN Qianxue
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1103-1106.   DOI: 10.3971/j.issn.1000-8578.2022.22.0090
Abstract ( 43 PDF (0KB)  ( 16 )   HTML ()
Glioblastoma is the most common primary malignant brain tumor. Despite large-scale researches have been carried out, the prognosis of glioblastoma is still not significantly improved. In recent years, with the application of multi-omics studies in glioblastoma, the understanding of glioblastoma has been deepened. The classification of glioblastoma has been revised; moreover, new therapeutic methods such as targeted therapy, immunotherapy and tumor treating fields have been developed on the basis of the standard therapy. This article reviews the recent progress in the diagnosis and treatment of glioblastoma.
Progress on Correlation Between Type 2 Diabetes Mellitus and Malignant Tumors
ZHOU Han, SHENG Deqiao
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1107-1111.   DOI: 10.3971/j.issn.1000-8578.2022.21.1324
Abstract ( 40 PDF (0KB)  ( 16 )   HTML ()
Type 2 diabetes mellitus and malignant tumors are two kinds of chronic diseases with tremendous impact on human health. Numerous epidemiological and clinical studies have shown that type 2 diabetes mellitus increases the risk of liver, pancreatic, endometrial, gallbladder, colorectal and breast cancers. Hyperglycemia can promote cancer cell proliferation, migration, invasion and immune escape through a variety of direct and indirect mechanisms. Insulin resistance and hyperinsulinemia can activate multiple signal transduction pathways through insulin/IGF-I signaling axis and promote tumorigenesis. Sustained chronic inflammatory responses can promote the development of cancer through DNA damage and pro-inflammatory factors. Gut microbiome dysbiosis is closely related to the occurrence of several gastrointestinal tumors. This paper reviews the progress on the correlation between type 2 diabetes mellitus and the progression of malignant tumors and the possible mechanisms.
Expression of ITGAV in Non-small Cell Lung Cancer and Its Relationship with Radioresistance
TANG Yuanhui, ZHU Shengming, CHAI Jingjing, HAN Jiahui, TIAN Chao, DENG Xingzhou, DUAN Qiwen
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1112-1118.   DOI: 10.3971/j.issn.1000-8578.2022.22.0177
Abstract ( 34 PDF (KB)  ( 11 )   HTML ()
Objective To investigate the relationship between the expression of ITGAV and the radiosensitivity of NSCLC cells. Methods The expression of ITGAV in NSCLC and its relationship to the prognosis of patients who received radiotherapy were analyzed using bioinformatics methods. Differences in radiosensitivity between radio-resistant cells and parent cells were verified by clone formation experiment, and the protein expression of ITGAV was detected by Western blot. The transfection efficiency of si-ITGAV was determined by Western blot and qRT-PCR analyses. The best ITGAV interference sequence was selected to transfect A549R and H1299R cells. Clone formation experiment and flow cytometry were used to detect clone formation, apoptosis and cell cycle of A549R and H1299R cells. Results The expression of ITGAV in NSCLC tissues was significantly higher than that in normal tissues (P<0.05), and NSCLC patients with high ITGAV expression had poor prognosis. The clonogenic ability of the si-ITGAV group was significantly lower than that of the negative control group at 4, 6, 8Gy irradiation (all P<0.05). After 6 Gy irradiation, the apoptosis of the si-ITGAV group was increased (PH1299R<0.0001, PA549R=0.0002), the proportion of G2/M phase cells to A549-siITGAV and H1299R-siITGAV cells was higher than that in the negative control group (PH1299R<0.0001, PA549R=0.0007). Conclusion Interfering with ITGAV expression can increase the radiosensitivity of NSCLC.
Effects of Cholesterol-lowering Agents on Proliferation, Invasion and Neutrophil Extracellular Trap Formation in Liver Cancer Cells
TANG Qiqi, LI Yan, SUN Guowei, LIANG Beibei, ZHAO Jian,
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1119-1125.   DOI: 10.3971/j.issn.1000-8578.2022.22.0280
Abstract ( 29 PDF (0KB)  ( 7 )   HTML ()
Objective To investigate the effects of cholesterol-lowering agents on the proliferation, stemness characters, migration, invasion, and neutrophil extracellular traps formation (NETs) formation in liver cancer cells. Methods ASPP2 or HMGCR gene was knocked down in mouse liver cancer cell Hepa1-6 to establish cells with high or low cholesterol, respectively. Simvastatin and berberine were used to reduce cholesterol synthesis. CCK-8 and plate cloning assays were conducted to detect the proliferation ability of liver cancer cells. Sphere formation assay and qRT-PCR were used to analyze the stemness character and expression of related genes. Wound-healing assay and Transwell assay were used to analyze the ability of cell migration and invasion. Immunofluorescence staining was carried out to analyze the effect of lipid-lowering agent on NETs formation. Results Cholesterollowering agents significantly inhibited the proliferation and stemness-related gene expression of Hepa1-6 cells (P<0.001), significantly inhibited the migration and invasion of Hepa1-6 cells (P<0.001), and significantly inhibited the neutrophil-induced invasion and formation of NETs (P<0.001). Conclusion Cholesterol-lowering agents suppress the proliferation and invasion via inhibiting the stemness characters and NETs formation in liver cancer cells. It is a potential strategy for the treatment of liver cancer metastasis.
Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells
ZHU Xiaoxia, JIA Yuqi, LIU Chang, GONG Tao, LI Gaopeng, ZHANG Hongwei, YU Baofeng
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1126-1133.   DOI: 10.3971/j.issn.1000-8578.2022.22.0157
Abstract ( 30 PDF (KB)  ( 9 )   HTML ()
Objective To study the effects and mechanisms of molecular targeted drug combination on multidriven proliferation hepatocellular carcinoma SK-Hep-1 cells. Methods Four molecular targeted drugs (HG6-64-1, Dasatinib, Crizotinib, and Sunitinib) were used to treat SK-Hep-1 cells, and the monophasic kinetic analysis curve and two-phase analysis curve were drawn. Western blot analysis was used to detect the effects of the above drugs on key signaling pathways in SK-Hep-1 cells. MTT assay was used to detect the effects of the above drugs and their combination on the proliferation of SK-Hep-1 cells. Results Compared with the monophasic kinetic analysis curve, the biphase analysis curve could better fit the effects of molecular targeted drugs on SK-Hep-1 cells, which predicted that the combination of HG6-64-1, Dasatinib, and MK-2206 could effectively inhibit the proliferation of SK-Hep-1 cells. Conclusion Two-phase kinetic analysis can quantitatively describe the response of multi-driven proliferation hepatocellular carcinoma SKHep-1 cells to molecular targeted therapy. The combination of HG6-64-1, Dasatinib, and MK-2206 is a potential drug combination for the treatment of hepatocellular carcinoma.
Jinfukang Inhibits Lung Cancer Metastasis by Regulating Immune Senescence
YAO Wang, QUE Zujun, YAO Jialiang, YU Pan, LUO Bin, TIAN Jianhui,
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1134-1138.   DOI: 10.3971/j.issn.1000-8578.2022.21.1474
Abstract ( 38 PDF (KB)  ( 5 )   HTML ()
Objective To explore the effect of immune senescence on lung cancer metastasis and reveal the mechanism of Fuzheng traditional Chinese medicine Jinfukang in the prevention and treatment of the metastasis. Methods A lung metastasis model of Lewis lung cancer cells was established in C57BL/6 mice with different ages (15 months, 6 months, and 2 months). Mice in the 6-month-old group were given Jinfukang intragastrically for 42 days. Pulmonary metastasis was analyzed by in vivo imaging, anatomical microscopic observation, and HE staining. The proportion of memory T cells and NK cells in peripheral blood was detected by flow cytometry. Results The lung metastatic tumor formation rate of 15-month-old and 6-month-old mice was significantly higher than that of 2-month-old mice (all P<0.05). Abundance of CD4+T cells in peripheral blood was positively correlated with age (2-month-old vs. 6-month-old, P=0.041; 2-month-old vs.15-month-old, P=0.041; 6-month-old vs.15-month-old, P=0.953). The abundance of NK cells was negatively correlated with age (2-month-old vs. 6-month-old, P=0.009; 2-month-old vs.15-monthold, P=0.009; 6-month-old vs.15-month-old, P=0.574). However, the survival time of mice in the Jinfukang group was longer (P>0.05) and the level of NK cells in peripheral blood was significantly higher (P=0.029) than those in the normal saline group. Conclusion Immune senescence can promote the metastasis of lung cancer. The prolongation of the survival time of mice administered with Jinfukang may be related to delaying immune senescence and increasing the number of NK cells.
Safety and Efficacy of Irreversible Electroporation Combined with Neoadjuvant Chemotherapy for Locally Advanced Pancreatic Cancer: A Meta-analysis
ZHAO Baoyin, LIANG Zhaojun, ZHANG Lixia, CHEN Shun, JIA Dong, WU Zhaohui, LI Bin, WANG Junke, MA Jun, YU Xiaohui
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1139-1145.   DOI: 10.3971/j.issn.1000-8578.2022.22.0367
Abstract ( 30 PDF (KB)  ( 4 )   HTML ()
Objective To evaluate the safety and efficacy of irreversible electroporation (IRE) combined with neoadjuvant chemotherapy in patients with locally advanced pancreatic cancer. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, China Biomedical Literature Database, CNKI, Wanfang, and VIP databases for articles dated from the establishment of each database to March 2022. Metaanalysis was performed using RevMan5.4 software. Results A total of 3970 patients with locally advanced pancreatic cancer were enrolled in eight studies, including one randomized controlled trial, four retrospective studies, and three prospective studies. The patients were divided into the combined therapy group with 344 patients and the chemotherapy-only group with 3626 patients. Meta-analysis showed that the overall survival of patients in the combined therapy group was significantly higher than that in the chemotherapy-only group (OR=4.52; 95%CI: 2.63-7.77; P<0.00001). However, no significant difference existed in the disease control rate between the combined therapy group and the chemotherapy-only group (OR=0.58; 95%CI: 0.02-18.74; P=0.76). Moreover, no significant difference existed in the disease progression between the two groups (OR=0.49; 95%CI: 0.23-1.02; P=0.06). The combination of neoadjuvant chemotherapy and IRE had no significant effect on the incidence of adverse reactions of gastrointestinal reaction (OR=0.37; 95%CI: 0.10-1.34; P=0.13) and bone marrow suppression (OR=0.61; 95%CI: 0.26-1.40; P=0.24). Conclusion IRE combined with neoadjuvant chemotherapy can remarkably improve the prognosis of patients with locally advanced pancreatic cancer, and significantly prolong the overall survival.
Expression and Clinical Significance of TM9SF3 in Lung Adenocarcinoma
YU Hualin, XU Yinghua, WANG Mingwei, LI Shuguang, ZHANG Wenwen, YANG Jinsong, LI Wei
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1146-1152.   DOI: 10.3971/j.issn.1000-8578.2022.22.0212
Abstract ( 35 PDF (KB)  ( 7 )   HTML ()
Objective To investigate the expression and clinical significance of TM9SF3 in lung adenocarcinoma (LUAD). Methods TCGA and GEPIA databases were used to screen the differentiallyexpressed TM9SF family molecules and analyze their effects on patient prognosis with LUAD. The expression and localization of TM9SF3 in LUAD patients were verified by a human proteomic mapping database, Western blot assay, and polymerase chain reaction assay. Herein, the GSEA was used for the signal pathway enrichment analysis of TM9SF3-related genes. Meanwhile, the TIMER database and CIBERSORT algorithm were used to analyze the correlation between differentially-expressed TM9SF3 and the degree of immune cell infiltration. Results The expression of TM9SF3 in LUAD was significantly increased and had a significant adverse effect on the prognosis of LUAD patients. In addition, immunoblotting and polymerase chain reaction confirmed that TM9SF3 was highly expressed in LUAD. Meanwhile, the genes related to TM9SF3 expression were mainly enriched in cell signaling pathways regulating immune cell activity. The expression of TM9SF3 was significantly correlated with the expression changes of six immune cells. Conclusion TM9SF3 is differentially expressed in LUAD and may be used as a potential prognostic marker for LUAD patients. TM9SF3 can also change the level of immune cell infiltration in LUAD patients and is expected to be a new potential target for LUAD immunotherapy.
Prognostic Factors in Patients with Advanced Lung Adenocarcinoma Treated with Icotinib
ZHANG Hongbin, ZHU Lingling, XIE Jiong, CAI Hongmei, JI Qiaoxia, LIANG Xiangcun, LI Hua, WANG Yuan, ZHAO Min
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1153-1158.   DOI: 10.3971/j.issn.1000-8578.2022.22.0174
Abstract ( 31 PDF (KB)  ( 2 )   HTML ()
Objective To investigate the relationship between the treatment of EGFR-TKI icotinib and the prognosis of advanced lung adenocarcinoma patients with EGFR mutation. Methods Patients with advanced lung adenocarcinoma who had EGFR19 and 21 gene mutations and were treated with EGFR-TKI icotinib were enrolled. The relationships of clinical features, EGFR gene mutation subtypes, and different sites with patients' prognosis were analyzed. Results A total of 101 patients with advanced lung adenocarcinoma were included in this study, including 58 cases (57.4%) of EGFR gene exon 19 deletion mutation (EGFR Del19) and 43 cases (42.6%) of EGFR gene exon 21 point mutation (EGFR L858R). The objective response rate was 63.4%. The mPFS and mOS were 13 months and 27 months, respectively. In addition, the mPFS and mOS of EGFR Del19 and EGFR19 mutation 746-750 were higher than those of EGFR L858R and other EGFR mutations, respectively. Meanwhile, multivariate analysis showed that the number of metastatic sites and pleural metastasis were independent influencing factors of patients' OS (P=0.027; P=0.041). The mOS of patients with the number of metastatic sites ≤3 and without pleural metastasis were 29 and 27 months, respectively. Conclusion There is no significant difference found in overall survival of advanced lung adenocarcinoma patients treated with icotinib among different EGFR mutation subtypes and sites. Herein, the overall survival time is longer in patients with less than three metastatic sites and without pleural metastasis.
Expression of YBX1 and FOXA1 in Gastric Cancer and Their Clinicopathological Significance
PEI Zhenghao, ZHANG Hu, WANG Jun, HAO Yang
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1159-1164.   DOI: 10.3971/j.issn.1000-8578.2022.22.0189
Abstract ( 28 PDF (KB)  ( 4 )   HTML ()
Objective To explore the expression levels of YBX1 and FOXA1 in gastric cancer tissues and determine their relationship with prognosis. Methods A total of 131 patients with gastric cancer were studied, and the corresponding adjacent normal tissues of each patient were selected as the control. qRTPCR and immunohistochemistry were used to detect the expression levels of YBX1 and FOXA1 in cancer tissues and adjacent tissues. The correlation between YBX1 and FOXA1 protein expression in gastric cancer tissues was expressed by Crammer’s V coefficient, and the correlation between YBX1 mRNA and FOXA1 mRNA was analyzed by Pearson method. Kaplan-Meier method was used to analyze the relationship between YBX1, FOXA1 protein expression in gastric cancer tissues and the 5-year overall survival rate of patients. Univariate and multivariate Cox regression analyses were used to analyze the factors affecting the prognosis of patients with gastric cancer. Results Compared with paracancerous tissue, the levels of FOXA1 and YBX1 in cancer tissues were lower and higher, respectively (P<0.05). A negative correlation was observed between YBX1 mRNA and FOXA1 mRNA in gastric cancer (r=?0.675, P<0.05). The expression of YBX1 and FOXA1 proteins in gastric cancer tissues was negatively correlated (Crammer’s V=?0.497, P<0.001). The expression of YBX1 and FOXA1 proteins in gastric cancer tissue was related to the degree of differentiation, lymph node metastasis, and TNM staging (P<0.05). The 5-year survival rate of the YBX1 negative expression group and the FOXA1 positive expression group were higher than those of the YBX1 positive expression group, and the FOXA1 negative expression group both P<0.05). TNM staging and YBX1 were independent risk factors for death in patients with gastric cancer (P<0.05), and FOXA1 was a protective factor (P<0.05). Conclusion YBX1 is highly expressed and FOXA1 is lowly expressed in gastric cancer tissues; they are closely related to the disease progression and prognosis of patients with gastric cancer.
Clinicopathological Significance of Poorly Differentiated Clusters in Liver Metastatic Lesions of Colorectal Carcinoma
PENG Hui, ZHANG Zhifa, WU Yingjun, ZHANG Xiaohan, ZHU Xianqiang, QIN Haili
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1165-1167.   DOI: 10.3971/j.issn.1000-8578.2022.22.0312
Abstract ( 28 PDF (KB)  ( 9 )   HTML ()
Objective To investigate the clinicopathological significance of PDC in liver metastases and analyze the correlation of PDC between liver metastases and primary lesions. Methods Retrospective analysis of 72 matched cases of colorectal cancer with liver metastases was performed. The PDC in primary tumor and liver metastatic lesion was interpreted synchronously, and then the relationship between PDC in liver metastasis and clinicopathological parameters was analyzed based on the correlation of PDC between primary and metastatic lesions. In addition, PDC were interpreted in accordance with Uenos’ standard. Results Among the 72 cases of liver metastasis of colorectal cancer, the number of G1, G2, and G3 graded by PDC was 28, 24, and 20, respectively. The PDC in liver metastatic lesion was correlated with tumor budding in liver metastatic lesion and PDC grade of primary lesion. No significant correlation with the size and number of liver metastatic lesion, the site, WHO grade, depth of invasion, lymph node metastasis, vascular invasion or tumor budding of the primary lesion was observed. Conclusion A positive correlation is found between liver metastasis of colorectal adenocarcinoma and PDC grade of primary tumor. Evaluating the PDC grade of primary tumor may provide a reference for the risk of liver metastasis.
Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database
LIANG Cuilyu, ZHANG Yin, CHEN Qiying
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1168-1174.   DOI: 10.3971/j.issn.1000-8578.2022.22.0183
Abstract ( 23 PDF (0KB)  ( 9 )   HTML ()
Objective To explore the potential adverse reactions of acalabrutinib by mining and analyzing the pharmacovigilance signal of acalabrutinib, to provide a reference for clinically safe and rational drug use. Methods Data related to acalabrutinib in the FAERS database were searched, and pharmacovigilance signals were obtained using the disproportionality measurement. Results A total of 3,155 reports of adverse events with acalabrutinib as the primary suspected drug were extracted, and 73 warning signals were detected involving 15 system organ classifications, 36 of which were not included in the drug instructions of acalabrutinib. The strong signals of acalabrutinib were mainly concentrated in various inflammatory and bleeding, anemia, contusion, atrial fibrillation, and so on. The largest number of system organ classification signals were focused on the blood and lymphatic system disorders, investigations, infections, and so on. In addition, the drug may cause tachycardia, brittle nails, and other warning signs. Through further analysis of gender-related adverse events, there were a total of 49 high-risk signals with gender differences found. Herein, male patients should pay attention to adverse reactions in bleeding, heart, urinary system, hypertension, and so on; meanwhile, female patients should be alert to adverse reactions in liver function, skin inflammation, and so on. Conclusion A total of 36 drug warning signs that are not mentioned in the instructions for acalabrutinib are mined using FAERS, and blood, infection, and cardiac toxicity require special attention. Thus, these signals should be detected promptly for effective prevention in clinical medication to reduce the risk of medication use for patients.
Biological Mechanism of Pyroptosis and Its Research Progress in Breast Cancer
DOU He, MA Shuang, ZHU Yue, LIU Yuqi, XIAO Min
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1175-1179.   DOI: 10.3971/j.issn.1000-8578.2022.22.0485
Abstract ( 70 PDF (KB)  ( 10 )   HTML ()
Pyroptosis is a newly discovered way of proinflammatory programmed cell death. Pyroptosis is mediated by caspase-1 (Caspase-1). Through the cleavage and activation of GSDM family proteins, small pores are formed on the cell membrane, thus rapid lysis of the cell membrane process, and then leads to intracellular inflammatory content release thereby causing inflammatory response. The three pyroptosis pathways are the classical pathway of Caspase-1, the non-classical pathway of Caspase-4, 5, and 11, and the special pathway of Caspase-3 or Hela cells. Pyroptosis plays an important role in the occurrence, invasion, and metastasis of breast cancer, and is closely related to the prevention and treatment of breast cancer. This article reviews the biological mechanism of pyroptosis and its research progress in breast cancer, to provide a new idea for clinicians in the treatment of breast cancer.
Progress on Tumor Infiltrating Lymphocytes in Immunotherapy and Prognosis Evaluation of Breast Cancer
HONG Chenchen, YAO Feng
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1180-1183.   DOI: 10.3971/j.issn.1000-8578.2022.22.0332
Abstract ( 36 PDF (KB)  ( 53 )   HTML ()
Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer in 2020. A large number of studies have proved that tumor infiltrating lymphocytes (TILs) are lethal to tumors and play an important role in identifying tumor antigens. Therefore, the application of TILs in clinical immunotherapy and prognosis assessment of breast cancer has attracted wide attention. In this review, the basic research progress and clinical application of TILs in different molecular types of breast cancer are reviewed, and the value of TILs in judging breast cancer prognosis and predicting the therapeutic effect of clinical immunotherapy is evaluated.
Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
WANG Yijie, ZHANG Gangwei, XU Chao, YAO Qinghua,
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1184-1189.   DOI: 10.3971/j.issn.1000-8578.2022.22.0429
Abstract ( 35 PDF (KB)  ( 5 )   HTML ()
With the rapid development of immunotherapy, an increasing number of immune checkpoint inhibitors have been used in clinical settings. Immunotherapy provides a new treatment option for patients with advanced colorectal cancer metastasis. Studies have confirmed that patients with metastatic colorectal cancer with dMMR/MSI-H status are more sensitive to immunotherapy and have a more objective and sustained clinical response than their counterparts. Gut microbiome has been proved to play a certain regulatory role in tumor immunotherapy response, and some bacteria can affect the efficacy of immune checkpoint inhibitors through the immune system or metabolic function of the body. With the progress of the study, the gut microbiome is expected to become not only the predictive biomarkers of curative effect of colorectal cancer immunotherapy, but it can also be a key regulatory factor influencing the results of colorectal cancer immunotherapy. For future clinical treatment, the use of immune checkpoint inhibitors may benefit patients with advanced colorectal cancer.
Epidemiological Study of New Cases of Peritoneal Metastases
YANG Rui, SU Yandong, MA Ru, AN Songlin, LIN Yulin, LI Yan
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1190-1194.   DOI: 10.3971/j.issn.1000-8578.2022.22.0270
Abstract ( 30 PDF (0KB)  ( 7 )   HTML ()
Peritoneal metastases (PM) are defined as the primary or secondary occurrence/progression of malignant tumor in peritoneum. PM were previously thought to be a terminal disease without effective treatment, with short survival and poor prognosis. With the change in the understanding of PM, the oncology communities regard it as a curable regional cancer metastasis, and create a comprehensive treatment technology system with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as the core, and establish professional PM treatment centers based on this. The professional PM treatment centers have significantly prolonged the survival of patients, and some patients can even achieve clinical cure. However, in China, there are very few professional PM treatment centers, but the number of PM patients is huge, and most of the patients can’t receive professional treatment, resulting in poor survival and prognosis. Based on the cancer statistics in 2015 published by China National Cancer Center Registry and clinical outcome literature on peritoneal metastasis, this paper uses clinical epidemiology methodology to calculate the number of newly diagnosed patients with peritoneal metastasis, to estimate the number of specialized peritoneal cancer centers required, to provide data support for the promotion of professional treatment technology system for PM in our country, and to boost the development of peritoneal oncology.
Non-alcoholic Fatty Liver Disease Affect Efficacy of Immune Checkpoint Inhibitors for Patients with Hepatocellular Carcinoma: Manifestations and Mechanisms
YUAN Ye, PENG Hui, TIAN De’an
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1195-1201.   DOI: 10.3971/j.issn.1000-8578.2022.22.0562
Abstract ( 31 PDF (KB)  ( 6 )   HTML ()
The number of patients with the combination of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) is gradually increasing. In recent years, the immunotherapy has become a new effective way to treat unresectable HCC. The clinical research revealed that the NAFLD could affect the efficacy of immunotherapy treating the HCC. But the mechanism is complicated. The major routes are CD8+PD-1+T cells increasing in NAFLD cause the deficiency in cell proliferation ability; Zn64 activates the anti-tumor immune response of the CSF1; PCSK9 downregulates the LDLR level to suppress the immune response of the CD8+T cells in tumor microenvironment; loss of the immune response induces the liver damage. Researches had indicated that the combination of lenvatinib, PKCa inhibitor, PCSK9 protein inhibition, ferroptosis inducer, and HIF2a small molecule inhibitor can improve the efficacy of immune checkpoint inhibitors for NAFLD-associated hepatocellular carcinoma. This review focuses on the impact of NAFLD on tumor microenvironment and how the NAFLD affect the immune check-point inhibitor effect and to discover the exact mechanism.
Cutaneous Squamous-cell Carcinoma During Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Report and Literature Review
LI Huiting, CAI Mei, BI Hui
Cancer Research on Prevention and Treatment. 2022, 49 (11): 1202-1204.   DOI: 10.3971/j.issn.1000-8578.2022.22.0258
Abstract ( 33 PDF (KB)  ( 9 )   HTML ()
Please wait a minute...
2022
Vol.49
No.10 
2022-10-25
pp.989-0
No.09
2022-09-25
pp.863-0
No.08
2022-08-25
pp.747-0
No.07
2022-07-25
pp.639-0
No.06
2022-06-25
pp.505-0
No.05
2022-05-25
pp.375-0
No.04
2022-04-25
pp.277-0
No.03
2022-03-25
pp.169-0
No.02
2022-02-25
pp.85-168
No.01
2022-01-25
pp.1-84
2021
Vol.48
No.12 
2021-12-25
pp.1061-0
No.11
2021-11-25
pp.985-0
No.10
2021-10-25
pp.909-0
No.09
2021-09-25
pp.827-0
No.08
2021-08-25
pp.745-0
No.07
2021-07-25
pp.659-0
No.06
2021-06-25
pp.565-0
No.05
2021-05-25
pp.441-0
No.04
2021-04-25
pp.321-0
No.03
2021-03-25
pp.219-0
No.02
2021-02-25
pp.109-0
No.01
2021-01-25
pp.1-0
2020
Vol.47
No.12 
2020-12-25
pp.905-0
No.11
2020-11-25
pp.811-0
No.10
2020-10-25
pp.727-0
No.09
2020-09-25
pp.649-0
No.08
2020-08-25
pp.573-0
No.07
2020-07-25
pp.479-0
No.06
2020-06-25
pp.403-0
No.05
2020-05-25
pp.319-0
No.04
2020-04-25
pp.227-0
No.03
2020-03-25
pp.149-0
No.02
2020-02-15
pp.83-0
No.01
2020-01-25
pp.1-0
2019
Vol.46
No.12 
2019-12-25
pp.1053-0
No.11
2019-11-25
pp.963-0
No.10
2019-10-05
pp.867-0
No.09
2019-09-25
pp.759-0
No.08
2019-08-25
pp.667-0
No.07
2019-07-25
pp.583-0
No.06
2019-06-25
pp.499-0
No.05
2019-05-25
pp.389-0
No.04
2019-04-25
pp.289-0
No.03
2019-03-25
pp.197-0
No.02
2019-02-25
pp.105-0
No.01
2019-01-25
pp.1-0
2018
Vol.45
No.12 
2018-12-25
pp.943-0
No.11
2018-11-25
pp.821-0
No.10
2018-10-25
pp.717-0
No.09
2018-09-25
pp.617-0
No.08
2018-08-25
pp.517-0
No.07
2018-07-25
pp.437-0
No.06
2018-06-25
pp.357-0
No.05
2018-05-25
pp.269-0
No.04
2018-04-25
pp.193-0
No.03
2018-03-25
pp.125-0
No.02
2018-02-25
pp.61-0
No.01
2018-01-25
pp.1-0
2017
Vol.44
No.12 
2017-12-25
pp.765-0
No.11
2017-11-25
pp.719-0
No.10
2017-10-20
pp.643-0
No.09
2017-09-25
pp.575-0
No.08
2017-08-25
pp.515-0
No.07
2017-07-25
pp.447-0
No.06
2017-06-25
pp.371-0
No.05
2017-05-25
pp.315-0
No.04
2017-04-25
pp.243-0
No.03
2017-03-25
pp.134-0
No.02
2017-02-25
pp.82-0
No.01
2017-01-25
pp.1-0
2016
Vol.43
No.12 
2016-12-25
pp.1013-0
No.11
2016-11-25
pp.921-0
No.10
2016-10-25
pp.825-0
No.09
2016-09-25
pp.733-0
No.08
2016-08-25
pp.653-0
No.07
2016-07-25
pp.545-0
No.06
2016-06-25
pp.437-0
No.05
2016-05-25
pp.321-0
No.04
2016-04-25
pp.245-0
No.03
2016-03-25
pp.169-0
No.02
2016-02-25
pp.93-0
No.01
2016-01-25
pp.1-0
2015
Vol.42
No.12 
2015-12-25
pp.1171-0
No.11
2015-11-25
pp.1063-0
No.10
2015-10-25
pp.955-0
No.08
2015-08-25
pp.751-0
No.09
2015-08-25
pp.1-0
No.07
2015-07-25
pp.643-0
No.06
2015-06-25
pp.535-0
No.05
2015-05-25
pp.427-0
No.04
2015-04-25
pp.319-0
No.03
2015-03-25
pp.215-0
No.02
2015-02-25
pp.103-0
No.01
2015-01-25
pp.1-0
2014
Vol.41
No.12 
2014-12-25
pp.1261-0
No.11
2014-11-25
pp.1159-0
No.10
2014-10-25
pp.1059-0
No.09
2014-09-25
pp.957-0
No.08
2014-08-25
pp.861-0
No.07
2014-07-25
pp.693-0
No.06
2014-06-25
pp.515-0
No.05
2014-05-25
pp.353-0
No.04
2014-04-25
pp.289-0
No.03
2014-03-25
pp.193-0
No.02
2014-02-25
pp.97-0
No.01
2014-01-25
pp.1-0
2013
Vol.40
No.12 
2013-12-25
pp.1109-0
No.11
2013-11-25
pp.1013-0
No.10
2013-10-25
pp.917-0
No.09
2013-09-25
pp.821-0
No.08
2013-08-25
pp.725-0
No.07
2013-07-25
pp.629-0
No.06
2013-06-25
pp.509-0
No.05
2013-05-25
pp.413-0
No.04
2013-04-25
pp.317-0
No.03
2013-03-25
pp.221-0
No.02
2013-02-25
pp.125-0
No.01
2013-01-25
pp.1-0
2012
Vol.39
No.12 
2012-12-25
pp.1407-0
No.11
2012-11-25
pp.1285-0
No.10
2012-10-25
pp.1163-0
No.09
2012-09-25
pp.1041-1162
No.08
2012-08-25
pp.887-0
No.07
2012-07-25
pp.765-0
No.06
2012-06-25
pp.615-0
No.05
2012-05-25
pp.493-614
No.04
2012-04-25
pp.245-492
No.03
2012-03-25
pp.245-366
No.02
2012-02-25
pp.123-244
No.01
2012-01-25
pp.1-122
2011
Vol.38
No.12 
2011-12-25
pp.1341-1462
No.11
2011-11-25
pp.1219-1340
No.10
2011-10-25
pp.1097-1218
No.09
2011-09-25
pp.975-1096
No.08
2011-08-25
pp.853-974
No.07
2011-07-25
pp.731-852
No.06
2011-06-25
pp.609-730
No.05
2011-05-25
pp.487-608
No.04
2011-04-25
pp.365-486
No.03
2011-03-25
pp.243-364
No.02
2011-02-25
pp.121-242
No.01
2011-01-25
pp.1-120
» Expression of KLF17 Protein in Human Colorectal Cancer Tissue and Its Correlation with Prognosis
  MENG Qingbin, WU Biao, XIAO Xinbo, SHAO Yongsheng, MIN Kai, QU Ziwei, FENG Yan, WANG Jing, YI Jilin
  Cancer Research on Prevention and Treatment. 2015 Vol. 42 (03): 256-260
» IDO Expression in Esophageal Squamous Cell Carcinoma and Its Relationship with Tumor Angiogenesis
  WANG Yu, JIA Yunlong, WANG Tingting, WANG Miao, DUAN Yuqing, WANG Hongyan, MENG Xianli, LIU Lihua
  Cancer Research on Prevention and Treatment. 2015 Vol. 42 (09): 892-896
»
 
  Cancer Research on Prevention and Treatment. 2014 Vol. 41 (01): 87-89
  Cited by: CSCD(1)
» Efficacy of Biliary Double Stents Implant on Malignant High Biliary Obstruction
  WU Zhonglin, SHAN Baoen, LI Shunzong, LI Zhigang, GU Tieshu, WU Yongchao
  Cancer Research on Prevention and Treatment. 2015 Vol. 42 (05): 498-501
  Cited by: CSCD(2)